These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12384636)

  • 41. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
    Konstantopoulos K; Mousa SA
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A cold start for oral glycoprotein IIb/IIIa antagonists.
    Curtin R; Fitzgerald DJ
    Eur Heart J; 2000 Dec; 21(24):1992-4. PubMed ID: 11102247
    [No Abstract]   [Full Text] [Related]  

  • 43. Glycoprotein IIb/IIIa receptor inhibitor use in unstable angina/non-ST-segment elevation myocardial infarction: an appropriate-use model for the emergency department.
    Hoekstra J
    J Emerg Med; 2000 Oct; 19(3 Suppl):13S-19S. PubMed ID: 11050379
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trials in interventional cardiology.
    Tcheng JE
    Thromb Haemost; 1997 Jul; 78(1):205-9. PubMed ID: 9198154
    [No Abstract]   [Full Text] [Related]  

  • 45. Correlation of inhibition of platelet aggregation with cardiovascular and bleeding outcomes in acute coronary syndromes.
    Wada R; Rohatagi S; Small D; Winters KJ; Salazar DE
    J Clin Pharmacol; 2010 Aug; 50(8):904-13. PubMed ID: 20147617
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The use of glycoprotein IIb/IIIa receptor inhibitors in unstable angina.
    Ageno W; Turpie AG
    G Ital Cardiol; 1999 Nov; 29(11):1357-65. PubMed ID: 10609142
    [No Abstract]   [Full Text] [Related]  

  • 47. Non-ST-segment elevation myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor: a case report.
    Zhang Z; Wan X; Liu Y; Lin X; Ni Z; Yang X; Zhang L
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):532-4. PubMed ID: 20724303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
    MacCallum EM; Hanlon SJ; Byrne KH
    Dimens Crit Care Nurs; 2000; 19(3):14-9. PubMed ID: 11998001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute coronary syndromes and diabetes mellitus.
    Trichon BH; Roe MT
    Diab Vasc Dis Res; 2004 May; 1(1):23-32. PubMed ID: 16305052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 'I can see clearly now': a new view on the use of IV GP IIb/IIIa inhibitors in acute coronary syndromes.
    Antman EM
    Eur Heart J; 2002 Sep; 23(18):1408-11. PubMed ID: 12208217
    [No Abstract]   [Full Text] [Related]  

  • 51. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
    Scirica BM; Cannon CP; Cooper R; Aster RH; Brassard J; McCabe CH; Charlesworth A; Skene AM; Braunwald E
    J Thromb Thrombolysis; 2006 Oct; 22(2):95-102. PubMed ID: 17008974
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exit of platelet glycoprotein-IIb/IIIa-receptor inhibitors?
    Adam PC; Pemberton J; Evemy KL
    Lancet; 2001 May; 357(9267):1535-6. PubMed ID: 11386297
    [No Abstract]   [Full Text] [Related]  

  • 53. Small-molecule glycoprotein IIb/IIIa antagonists and bleeding risk in women: too much of a good thing?
    Leopold JA
    Circulation; 2006 Sep; 114(13):1344-6. PubMed ID: 17000918
    [No Abstract]   [Full Text] [Related]  

  • 54. Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questions.
    Mahaffey KW; Harrington RA
    JAMA; 2007 Feb; 297(6):636-9. PubMed ID: 17299199
    [No Abstract]   [Full Text] [Related]  

  • 55. Decision making with cardiac troponin tests.
    Antman EM
    N Engl J Med; 2002 Jun; 346(26):2079-82. PubMed ID: 12087146
    [No Abstract]   [Full Text] [Related]  

  • 56. Competing pharmacological strategies during PCI-analysis of a prematurely terminated trial.
    Kimmelstiel C
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1010-1. PubMed ID: 21598352
    [No Abstract]   [Full Text] [Related]  

  • 57. Effect of glycoprotein IIb/IIIa inhibitors on the individual components of composite endpoints used in clinical trials of unstable angina and non-Q-wave myocardial infarction.
    Brown DL; Fann CS; Chang CJ
    Cardiovasc Drugs Ther; 2000 Jun; 14(3):253-8. PubMed ID: 10935147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral glycoprotein IIb/IIa antagonists for unstable angina--is there still a chance for the oral substances?
    Darius H
    Thromb Res; 2001 Sep; 103 Suppl 1():S117-24. PubMed ID: 11567679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Which patients with acute coronary syndrome without ST segment elevation should be handled invasively/interventionally when?].
    Kaiser C; Balmelli N; Pfisterer M
    Ther Umsch; 2002 Feb; 59(2):87-91. PubMed ID: 11887555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence-based emergency medicine. Use of platelet glycoprotein IIb/IIIa inhibitors in patients with unstable angina and non-ST-segment elevation myocardial infarction.
    Lang ES; Afilalo M
    Ann Emerg Med; 2002 Nov; 40(5):518-20. PubMed ID: 12399796
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.